MX2009000320A - Formulaciones de liberacion controlada. - Google Patents

Formulaciones de liberacion controlada.

Info

Publication number
MX2009000320A
MX2009000320A MX2009000320A MX2009000320A MX2009000320A MX 2009000320 A MX2009000320 A MX 2009000320A MX 2009000320 A MX2009000320 A MX 2009000320A MX 2009000320 A MX2009000320 A MX 2009000320A MX 2009000320 A MX2009000320 A MX 2009000320A
Authority
MX
Mexico
Prior art keywords
release
core
controlled
formulations
immediate
Prior art date
Application number
MX2009000320A
Other languages
English (en)
Inventor
Siva Rama K Nutalapati
Kristin Arnold
Ishari Piya
Original Assignee
Mutual Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mutual Pharmaceutical Co filed Critical Mutual Pharmaceutical Co
Publication of MX2009000320A publication Critical patent/MX2009000320A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Se describen en la presente formulaciones de liberación controlada que presentan cinéticas sustancialmente de orden cero. Las formulaciones incluyen un núcleo que comprende un agente activo nuclear un excipiente de cera sustancialmente recubierto con un recubrimiento de liberación prolongada. La formulación incluye opcionalmente una porción de liberación inmediata que comprende un agente activo de liberación inmediata en forma de, por ejemplo, un recubrimiento dispuesto sobre al menos una porción del núcleo. Además se describen formulaciones de combinación de fexofenadina/pseudoefedrina que sustancialmente no muestran ningún efecto por la comida.
MX2009000320A 2006-07-11 2007-07-11 Formulaciones de liberacion controlada. MX2009000320A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81991406P 2006-07-11 2006-07-11
US85977206P 2006-11-17 2006-11-17
PCT/US2007/015897 WO2008008434A1 (en) 2006-07-11 2007-07-11 Controlled-release formulations

Publications (1)

Publication Number Publication Date
MX2009000320A true MX2009000320A (es) 2009-06-05

Family

ID=38656800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000320A MX2009000320A (es) 2006-07-11 2007-07-11 Formulaciones de liberacion controlada.

Country Status (12)

Country Link
US (1) US20080095843A1 (es)
EP (1) EP2046299A1 (es)
JP (1) JP2009543780A (es)
KR (1) KR20090037930A (es)
AU (1) AU2007272951A1 (es)
CA (1) CA2658170A1 (es)
CO (1) CO6180499A2 (es)
IL (1) IL196396A0 (es)
MX (1) MX2009000320A (es)
NO (1) NO20090185L (es)
RU (1) RU2009104001A (es)
WO (1) WO2008008434A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20100143471A1 (en) * 2007-03-21 2010-06-10 Lupin Limited Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
NZ588695A (en) * 2008-03-21 2012-11-30 Mylan Pharmaceuticals Inc Extended release forumulation containing a wax and ciprofloxacin
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
AU2010250750A1 (en) * 2009-05-22 2011-12-08 Alkem Laboratories Ltd. Pharmaceutical composition of olanzapine and process for their preparation
WO2010138439A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
WO2011021594A1 (ja) * 2009-08-18 2011-02-24 国立大学法人東北大学 持続性ドラッグデリバリーシステム
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011061616A2 (en) * 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10485770B2 (en) * 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
WO2011161504A1 (en) * 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
JP6121990B2 (ja) * 2011-05-13 2017-04-26 イービー アイピー ハイブリタブス ビー．ブイ． 薬物送達システム
ES2628303T3 (es) * 2011-06-01 2017-08-02 Fmc Corporation Formas de dosis sólidas de liberación controlada
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法
JP6176840B2 (ja) * 2012-06-29 2017-08-09 高田製薬株式会社 フェキソフェナジン顆粒製剤及びその製造方法
RU2018141241A (ru) 2012-11-30 2019-01-24 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
EA201500742A1 (ru) 2013-02-05 2015-12-30 Пердью Фарма Л.П. Защищенные от нецелевого использования фармацевтические композиции
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP2016522188A (ja) * 2013-05-03 2016-07-28 シンダックス ファーマシューティカルズ，インク． 癌の処置方法
KR101561345B1 (ko) * 2013-10-17 2015-10-16 대원제약주식회사 제어방출되는 프로피온산 계열의 약제학적 조성물
AU2015237723B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3355877A4 (en) * 2015-09-30 2019-05-15 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
JP6286096B1 (ja) * 2017-08-01 2018-02-28 ロート製薬株式会社 医薬用錠剤
JP2019218313A (ja) 2018-06-21 2019-12-26 沢井製薬株式会社 プソイドエフェドリン又はその薬学的に許容される塩を含有する徐放製剤
CN113230235B (zh) * 2021-04-15 2022-11-11 海南普利制药股份有限公司 含地氯雷他定的复方缓释胶囊及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2189007C (en) * 1994-05-18 2004-03-02 Daniel R. Henton Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
TR200000517T2 (tr) * 1997-08-26 2000-08-21 Hoechst Marion Roussel, Inc. Piperidinoalkanol-Konjesyon azaltıcıdan oluşan kombinasyona yönelik farmasötik kompozisyon.
SK287684B6 (sk) * 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
US6613357B2 (en) * 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
US7147870B2 (en) * 2000-01-13 2006-12-12 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
AU2001261165A1 (en) * 2000-05-05 2001-11-20 Aventis Pharmaceuticals Inc. Packaging regimen of pseudoephedrine hydrochloride and fexofenadine hydrocloride
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) * 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
PL366576A1 (en) * 2001-04-09 2005-02-07 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
ES2301662T3 (es) * 2001-07-31 2008-07-01 Texcontor Etablissement Polimorfo de clorhidrato de fexofenadina.
EP1474392A1 (en) * 2002-06-10 2004-11-10 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
KR20040037045A (ko) * 2004-04-12 2004-05-04 최재승 경구용 항알레르기 복합제제의 조성물 및 그 제조방법
KR20070007196A (ko) * 2004-04-26 2007-01-12 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"

Also Published As

Publication number Publication date
WO2008008434A1 (en) 2008-01-17
CA2658170A1 (en) 2008-01-17
NO20090185L (no) 2009-03-31
KR20090037930A (ko) 2009-04-16
CO6180499A2 (es) 2010-07-19
AU2007272951A1 (en) 2008-01-17
US20080095843A1 (en) 2008-04-24
EP2046299A1 (en) 2009-04-15
IL196396A0 (en) 2009-09-22
JP2009543780A (ja) 2009-12-10
AU2007272951A2 (en) 2009-03-05
RU2009104001A (ru) 2010-08-20

Similar Documents

Publication Publication Date Title
MX2009000320A (es) Formulaciones de liberacion controlada.
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
ATE476176T1 (de) Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
WO2007135193A3 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool
WO2007073702A3 (es) Comprimido multicapa con combinación de triple liberación
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
WO2009117130A3 (en) Extended release forumulation containing a wax
MX350380B (es) Formas de dosificacion solida de liberacion modificada en el orden de cero.
WO2007041367A3 (en) Oral composition containing a salivation inducing agent
UA88477C2 (ru) Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
SG157415A1 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
HRP20130715T1 (hr) Oralni oblik doziranja osiguran protiv zlouporabe koji sadrži (1r, 2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol
WO2007036952A3 (en) Novel sustained release dosage form
TR200200562T2 (tr) Vücutta kontrollü şekilde salgılanabilen ve nahoş tadı önleyebilen ağızdan alınmaya mahsus farmasötik bileşimler
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
WO2007117431A3 (en) Use of rasagiline for the treatment of restless legs syndrome
HK1091137A1 (en) Extended release coated minitablets of venlafaxinehydrochloride
HK1172845A1 (en) Novel pharmaceutical formulations against drug misuse
WO2009125981A3 (ko) 약제학적 제제
WO2007021968A3 (en) Sustained release antihistamine and decongestant composition
WO2011101866A3 (en) Gastric retention formulation containing baclofen
WO2005027843A3 (en) Chronotherapeutic dosage forms
IL193023A0 (en) Dipyridamole extended-release formulations and process for preparing same
PT1795186E (pt) Preparado farmacêutico compreendendo flupirtina com libertação controlada da substância activa
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal